2018 TCR-Based Antibody and T-Cell Immunotherapy Report Package: Two Full Reports Covering TCR-based T-cell and Recombinant Antibody (Fusion Protein) Immunotherapy of Cancer

The "Report Package: TCR-Based Antibody and T-Cell Immunotherapy" report has been added to ResearchAndMarkets.com's offering.
T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of effective cancer therapeutics.
However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy.
This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy of cancer.

DUBLIN, June 14, 2018 /PRNewswire/ --

The "Report Package: TCR-Based Antibody and T-Cell Immunotherapy" report has been added to ResearchAndMarkets.com's offering.

T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of effective cancer therapeutics.

Both treatment modalities have in common that they are directed to intracellular targets which are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy.

While TCR engineered T-cells exert their effector function via the cytotoxicity of T-cells, antibodies can act via their intrinsic effects (ADCC, CDC) or by enhancing them as antibody-drug conjugates or T-cell redirecting bispecific antibodies.

This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy of cancer.

The original reports were published in January and May 2018, respectively:

"Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends"
"TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals"

For more information about this report visit https://www.researchandmarkets.com/research/kp2hbd/2018_tcrbased?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/2018-tcr-based-antibody-and-t-cell-immunotherapy-report-package-two-full-reports-covering-tcr-based-t-cell-and-recombinant-antibody-fusion-protein-immunotherapy-of-cancer-300666411.html

SOURCE Research and Markets